Performance Evaluation of the CS-5100 Coagulation Analyzer for Special Coagulation Parameters
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The CS-5100 high-throughput automated coagulometer (Sysmex, Japan) can perform general and special coagulation assays. We evaluated the performance of the CS-5100 coagulometer to measure fibrinogen degradation product (FDP), plasma level of unfractionated heparin (UFH), low molecular weight heparin (LMWH), and direct oral anticoagulants (DOACs). Methods: Precision, linearity, and carryover rate of the CS-5100 while measuring FDP, UFH, and LMWH were validated. Precision and linearity were validated for measurements of DOACs. Results of FDP measurement using CS-5100 were compared to those using the currently used STA-R coagulometer (Diagnostica Stago, France). The reference range of FDP was established. All evaluation procedures were in accordance with Clinical and Laboratory Standards Institute guidelines. Results: CS-5100 displayed good precision, linearity, and carryover rate for measuring FDP, UFH, LMWH, and DOACs. The FDP level measured with the CS-5100 and STA-R coagulometers correlated well. The reference range of FDP with CS-5100 was 0.0 to 3.48 µg/mL. Conclusions: The CS-5100 coagulometer has acceptable analytical performance in measuring special coagulation parameters. It is suitable for the reliable measurement of plasma FDP and anticoagulant levels in clinical laboratories.
Abstract
Background: The CS-5100 high-throughput automated coagulometer (Sysmex, Japan) can perform general and special coagulation assays. We evaluated the performance of the CS-5100 coagulometer to measure fibrinogen degradation product (FDP), plasma level of unfractionated heparin (UFH), low molecular weight heparin (LMWH), and direct oral anticoagulants (DOACs). Methods: Precision, linearity, and carryover rate of the CS-5100 while measuring FDP, UFH, and LMWH were validated. Precision and linearity were validated for measurements of DOACs. Results of FDP measurement using CS-5100 were compared to those using the currently used STA-R coagulometer (Diagnostica Stago, France). The reference range of FDP was established. All evaluation procedures were in accordance with Clinical and Laboratory Standards Institute guidelines. Results: CS-5100 displayed good precision, linearity, and carryover rate for measuring FDP, UFH, LMWH, and DOACs. The FDP level measured with the CS-5100 and STA-R coagulometers correlated well. The reference range of FDP with CS-5100 was 0.0 to 3.48 µg/mL. Conclusions: The CS-5100 coagulometer has acceptable analytical performance in measuring special coagulation parameters. It is suitable for the reliable measurement of plasma FDP and anticoagulant levels in clinical laboratories.
참고문헌 (27)
- Ratzinger F, "Evaluation of the automated coagulation analyzer CS-5100 and its utility in high throughput laboratories", Clin Chem Lab Med, 52, pp.1193~1202 (2014)
- Geens T, "Validation of the Sysmex CS5100 coagulation analyzer and comparison to the Stago STA-R analyzer for routine coagulation parameters", Int J Lab Hematol, 37, pp.372~381 (2015)
- Chen L, "Performance evaluation of the Sysmex CS-5100 automated coagulation analyzer", Clin Lab, 61, pp.653~660 (2015)
- Flieder T, "The Sysmex CS-5100 coagulation analyzer offers comparable analytical performance and excellent throughput capabilities", Pract Lab Med, 6, pp.38~47 (2016)
- Camici GG, "Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation : a potential treatment strategy for drug-eluting stents", Circulation, 114, pp.1512~1521 (2006)
- Clinical and Laboratory Standards Institute, "Evaluation of precision of quantitative measurement procedures; approved guideline" (2014), Clinical and Laboratory Standards Institute
- Clinical and Laboratory Standards Institute, "Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline" (2003), Clinical and Laboratory Standards Institute
- Clinical and Laboratory Standards Institute, "Preliminary evaluation of quantitative clinical laboratory measurement procedures; approved guideline" (2014), Clinical and Laboratory Standards Institute
- Clinical and Laboratory Standards Institute, "Measurement procedure comparison and bias estimation using patient samples; approved guideline" (2013), Clinical and Laboratory Standards Institute
- Clinical and Laboratory Standards Institute, "Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline" (2008), Clinical and Laboratory Standards Institute
- McPherson RA, "Henry’s clinical diagnosis and management by laboratory methods" (2017), Elsevier
- Gardiner C, "Recommendations for evaluation of coagulation analyzers", Lab Hematol, 12, pp.32~38 (2006)
- Garcia DA, "Parenteral anticoagulants : Antithrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 141, pp.e24S~e43S (2012)
- Vandiver JW, "Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin", Pharmacotherapy, 32, pp.546~558 (2012)
- Baluwala I, "Therapeutic monitoring of unfractionated heparin-trials and tribulations", Expert Rev Hematol, 10, pp.595~605 (2017)
- Gouin-Thibault I, "Safety profile of different low-molecular weight heparins used at therapeutic dose", Drug Saf, 28, pp.333~349 (2005)
- Thomas O, "Monitoring low molecular weight heparins at therapeutic levels : dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays", PLoS One, 10, pp.e0116835~ (2015)
- Samama MM, "Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls : results of a multicenter field trial", Clin Appl Thromb Hemost, 18, pp.150~158 (2012)
- Mueck W, "Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery", Clin Pharmacokinet, 47, pp.203~216 (2008)
- Perzborn E, "In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor", J Thromb Haemost, 3, pp.514~521 (2005)
- Kubitza D, "Absence of clinically relevant interactions between rivaroxaban--an oral, direct Factor Xa inhibitor--and digoxin or atorvastatin in healthy subjects", J Int Med Res, 40, pp.1688~1707 (2012)
- Douxfils J, "Measurement of non-VKA oral anticoagulants versus classic ones : the appropriate use of hemostasis assays", Thromb J, 12, pp.24~ (2014)
- Lippi G, "Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants(DOACs) : is there consensus", Clin Chem Lab Med, 53, pp.185~197 (2015)
- Adcock DM, "Direct oral anticoagulants(DOACs)in the laboratory : 2015 review", Thromb Res, 136, pp.7~12 (2015)
- Harenberg J, "Determination of rivaroxaban in human plasma samples", Semin Thromb Hemost, 38, pp.178~184 (2012)
- Tripodi A, "The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients : results of an in vitro study", J Thromb Haemost, 9, pp.226~228 (2011)
- Blech S, "The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans", Drug Metab Dispos, 36, pp.386~399 (2008)